Trials / Completed
CompletedNCT06279234
A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus
A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Escalating Oral Doses of PF-06954522 in Adult Participants With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple escalating oral doses of PF-06954522 in adult participants with inadequately controlled type 2 diabetes mellitus (T2DM) on metformin (Part A) and optionally in non-diabetic participants with obesity (Part B).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Oral tablet |
| DRUG | Rosuvastatin | Oral tablet |
| DRUG | Midazolam | Oral suspension |
| DRUG | Omeprazole | Oral tablet |
| DRUG | PF-06954522 | Oral tablet |
Timeline
- Start date
- 2024-02-20
- Primary completion
- 2025-04-11
- Completion
- 2025-04-11
- First posted
- 2024-02-28
- Last updated
- 2025-06-03
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06279234. Inclusion in this directory is not an endorsement.